Page last updated: 2024-11-12

azd 0837

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

AZD 0837: anticoagulant prodrug of AR-H067637 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9961205
CHEMBL ID4297593
SCHEMBL ID9914214
MeSH IDM0549199

Synonyms (22)

Synonym
atecegatran fexenetil
atecegatran fexenetil [inn]
4gu1d587jv ,
azd 0837
atecegatran metoxil
atecegatran metoxil [inn]
2-azetidinecarboxamide, 1-((2r)-(3-chloro-5- (difluoromethoxy)phenyl)hydroxyacetyl)-n-((4-(imino(methoxyamino)methyl)phenyl)methyl)-, (2s)-
azd0837
unii-4gu1d587jv
azd 0837 [who-dd]
2-azetidinecarboxamide, 1-((2r)-(3-chloro-5-(difluoromethoxy)phenyl)hydroxyacetyl)-n-((4-(imino(methoxyamino)methyl)phenyl)methyl)-, (2s)-
(2s)-1-((2r)-2-(3-chloro-5-(difluoromethoxy)phenyl)-2-hydroxyacetyl)-n-((4-((z)-n'-methoxycarbamimidoyl)phenyl)methyl)azetidine-2-carboxamide
2-azetidinecarboxamide, 1-((2r)-2-(3-chloro-5-(difluoromethoxy)phenyl)-2-hydroxyacetyl)-n-((4-(imino(methoxyamino)methyl)phenyl)methyl)-, (2s)-
atecegatran metoxil [who-dd]
SCHEMBL9914214
DB12507
CHEMBL4297593
(2s)-1-[(2r)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-n-[[4-[(e)-n'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide
(2s)-1-[(2r)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-n-[[4-[(z)-n'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide
HY-10273
CS-0002522
AKOS040750618

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A numerically higher incidence of serious adverse events was observed with 350mg bid AZD0837 compared with 150mg bid, with six of 13 being cardiac related, all with different diagnoses."( Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Jensen, E; Olsson, SB; Panfilov, S; Rasmussen, LH; Tveit, A; Wåhlander, K; Wessman, P, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"AZD0837 was rapidly absorbed, with a mean oral bioavailability of 22 - 52%, and bioconverted to the active form, AR-H067637."( Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Cullberg, M; Dunér, K; Elg, M; Eriksson, UG; Jensen, E; Johansson, S; Wåhlander, K; Wollbratt, M, 2011
)
0.37
" Bioavailability over the gut-wall was estimated to be high in duodenum (70%) compared to the small intestine (25%)."( A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.
Bergstrand, M; Eriksson, UG; Karlsson, MO; Söderlind, E; Weitschies, W, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Concomitant dosing with ketoconazole increased the area under the plasma concentration-time curve for AZD0837 (by 99%) and for AR-H067637 (by 51%)."( Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs.
Bottner, P; Eriksson, UG; Knutson, L; Lennernäs, H; Lundahl, A; Matsson, EM; Palm, JE, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's17 (89.47)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (36.84%)5.53%
Reviews5 (26.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (36.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]